CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. In particular, we are focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. Source
No articles found.
Infinity Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicate...
Infinity Pharmaceuticals, Inc. is an innovative...
American International Industries, Inc. (OTCQB: AMIN) is a diversified holding com...
American International Industries, Inc. (OTCQB:...
At Delee were fundamentally changing not only the way cancer is detected but also...
At Delee were fundamentally changing not only ...
Adial Pharmaceuticals, Inc. ("the Company") is a clinical-stage biopharmaceutical ...
Adial Pharmaceuticals, Inc. ("the Company") is ...
Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...
Stoke is pioneering a new way to treat the unde...
Allenaâs lead product candidate, reloxaliase, is a first-in-class, oral enzyme t...
Allenaâs lead product candidate, reloxaliase,...
NantKwest is an innovative clinical-stage immunotherapy company focused on harness...
NantKwest is an innovative clinical-stage immun...
Join the National Investor Network and get the latest information with your interests in mind.